TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28039399

Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise (VIG; n = 18)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Moderate intensity exercise (MOD; n = 20)
Number of subjects: 38
Study: 24491067

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) including a minimum of 90 minutes of adapted physical activity 5 days/week
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 22182258

Group type: EXPERIMENTAL
Intervention: Probiotic chewing gum containing L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Probiotic chewing gum
Number of subjects: 25
Study: 20410514

Group type: EXPERIMENTAL
Intervention: Step-up approach (percutaneous drainage followed by minimally invasive retroperitoneal necrosectomy if necessary)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Open necrosectomy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Step-up approach
Number of subjects: 88
Study: 18622999

Group type: EXPERIMENTAL
Intervention: Nurse-led patient education interventions
Number of subjects: 7
Study: 16643581

Group type: EXPERIMENTAL
Intervention: 5 mg haloperidol in 500 mL of normal saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: 500 mL of normal saline (placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Open trial with haloperidol after placebo failure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Side effects of haloperidol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Relapse after treatment
Number of subjects: 40
Study: 12826040

Group type: EXPERIMENTAL
Intervention: Intravenous ZD9331 (n=30), on days 1 and 8 of a 3‐week cycle
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intravenous gemcitabine (n=25), once a week for 7 weeks followed by a 1‐week rest, then on days 1, 8 and 15 of a 4‐week cycle
Number of subjects: 55
Study: 11392162

Group type: EXPERIMENTAL
Intervention: Untreated essential hypertension
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 25
Study: 8794969

Group type: EXPERIMENTAL
Intervention: Chairside test measuring GCF levels of AST
Number of subjects: 121

Group type: COMPARATOR
Intervention: Scaling and root planing (for patients)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Supragingival prophylaxis (for control subjects)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Measurements of GCF volume, gingival inflammation, and probing depth
Number of subjects: 121
Study: 1377838

Group type: EXPERIMENTAL
Intervention: Supplemental enteral diet with arginine, RNA, and omega-3 fatty acids
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard enteral diet
Number of subjects: 85
Study: 6696222

Group type: EXPERIMENTAL
Intervention: Epidural methadone
Number of subjects: 178

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 178

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 178
Study: 31331907

Group type: EXPERIMENTAL
Intervention: Exubera (insulin human [rDNA origin], inhaled powder)
Number of subjects: 7439

Group type: COMPARATOR
Intervention: Other diabetes treatments (control)
Number of subjects: 7439
Study: 29992747

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM) intervention (n = 60)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Wait-list control condition (n = 51)
Number of subjects: 115
Study: 26875171

Group type: EXPERIMENTAL
Intervention: With peers
Number of subjects: 207

Group type: COMPARATOR
Intervention: Alone
Number of subjects: 207
Study: 24818542

Group type: EXPERIMENTAL
Intervention: 4 mg intravenous ondansetron
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 20 mg intravenous metoclopramide
Number of subjects: 258

Group type: COMPARATOR
Intervention: Saline solution placebo
Number of subjects: 258
Study: 22268817

Group type: EXPERIMENTAL
Intervention: Rapydan (7% lidocaine and 7% tetracaine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ametop (4% tetracaine)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 21170697

Group type: EXPERIMENTAL
Intervention: 30 mg EPs 7630 daily
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: 60 mg EPs 7630 daily
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: 90 mg EPs 7630 daily
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 17191265

Group type: COMPARATOR
Intervention: Standard olanzapine tablets
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Orally disintegrating olanzapine
Number of subjects: 38
Study: 15718656

Group type: EXPERIMENTAL
Intervention: Intelligent Knee Sleeve
Number of subjects: 0
Study: 12005078

Group type: EXPERIMENTAL
Intervention: Heptavalent CRM197 pneumococcal conjugate vaccine (PCV)
Number of subjects: 37868
Study: 9807847

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane and Isoflurane anesthesia
Number of subjects: 80
Study: 7659241

Group type: EXPERIMENTAL
Intervention: Low-cost, technician-administered anxiety reduction intervention (removing heart rate feedback, cognitive distraction, controlled breathing techniques)
Number of subjects: 0
Study: 2747301

Group type: EXPERIMENTAL
Intervention: Telephone family assessment intervention
Number of subjects: 224
Study: 57448

Group type: EXPERIMENTAL
Intervention: Oestrogen treatment for five years
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Delayed onset of oestrogen treatment (3 to 6 years)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oestrogen treatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oestrogen therapy
Number of subjects: 63
Study: 31035474

Group type: EXPERIMENTAL
Intervention: Tomato Nutrient Complex (TNC) 15 mg lycopene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tomato Nutrient Complex (TNC) 30 mg lycopene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tomato Nutrient Complex (TNC) 5 mg lycopene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synthetic lycopene 15 mg
Number of subjects: 0
Study: 28590377

Group type: EXPERIMENTAL
Intervention: Brace intervention with a thoracolumbosacral orthosis (TLSO)
Number of subjects: 168
Study: 26688484

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 23863812

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg and Valsartan 160 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pravastatin 40 mg and placebo
Number of subjects: 48

Group type: COMPARATOR
Intervention: Valsartan 160 mg and placebo
Number of subjects: 48
Study: 21592232

Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg daily for 12 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Solifenacin 5mg daily for 12 weeks
Number of subjects: 56
Study: 19628740

Group type: EXPERIMENTAL
Intervention: Alcon AcrySof Natural intraocular lens (ANIOL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Alcon AcrySof three‐piece acrylic intraocular lens (AIOL)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Serum concentrations of L
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Serum concentrations of Z
Number of subjects: 42
Study: 17019636

Group type: EXPERIMENTAL
Intervention: Catheter ablation of atrial fibrillation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Catheter ablation of atrial fibrillation including repeat procedures
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Catheter ablation of atrial fibrillation in paroxysmal AF patients considered optimal candidates
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Major complications
Number of subjects: 200
Study: 12807578

Group type: EXPERIMENTAL
Intervention: Group exercise (EX) program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Recreational therapy (C)
Number of subjects: 20
Study: 10969220

Group type: EXPERIMENTAL
Intervention: Continuous nebulization of salbutamol (15 mg during the first hour and 12.5 mg over the next 5 hours)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intermittent nebulization of salbutamol (5 mg every 20 minutes during the first hour and 2.5 mg hourly over the next 5 hours)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both groups (continuous and intermittent nebulization)
Number of subjects: 42
Study: 8796387

Group type: EXPERIMENTAL
Intervention: Low PaO2 (approximately 50 mmHg) Low PEEP (approximately 1 cmH2O)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High PaO2 (approximately 80 mmHg) High PEEP (approximately 10 cmH2O)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low PaO2 (approximately 50 mmHg) High PEEP (approximately 10 cmH2O)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High PaO2 (approximately 80 mmHg) Low PEEP (approximately 1 cmH2O)
Number of subjects: 13
Study: 1535588

Group type: EXPERIMENTAL
Intervention: Enoximone (E)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Dopamine (D) and Glyceroltrinitrate (G)
Number of subjects: 13
Study: 6387965

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg + Sotalol (STL) 320 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30264419

Group type: EXPERIMENTAL
Intervention: Behavioural activation therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Guided self-help therapy
Number of subjects: 21
Study: 31074652

Group type: EXPERIMENTAL
Intervention: 20 mM ascorbic acid (AA) during the HS diet
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 100 µM apocynin during the HS diet
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 10 µM Tempol during the HS diet
Number of subjects: 29

Group type: COMPARATOR
Intervention: High-sodium diet (HS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-sodium diet (LS)
Number of subjects: 29
Study: 28306481

Group type: EXPERIMENTAL
Intervention: Health message video about mortality risk to smokers
Number of subjects: 999

Group type: COMPARATOR
Intervention: Control video on a health topic unrelated to smoking
Number of subjects: 999
Study: 25465111

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 1644

Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 1644
Study: 23352379

Group type: EXPERIMENTAL
Intervention: Sitagliptin 25 mg daily
Number of subjects: 129

Group type: COMPARATOR
Intervention: Glipizide (initiated with 2.5 mg daily, titrated up to 10 mg twice daily)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 129

Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 129
Study: 21402328

Group type: EXPERIMENTAL
Intervention: Gaming console exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: Treadmill or cycle ergometer exercise
Number of subjects: 19
Study: 18548148

Group type: EXPERIMENTAL
Intervention: Reduction in daily sodium intake of 1840 mg/day
Number of subjects: 11550

Group type: EXPERIMENTAL
Intervention: Reduction in dietary sodium from 1200 mg/day to 2400 mg/day
Number of subjects: 11550
Study: 16570051

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 10,000‐20,000 IU three times weekly plus best standard treatment (BST)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Best standard treatment (BST) only
Number of subjects: 182
Study: 12755663

Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160 mg/day)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Conventional antipsychotics, olanzapine, risperidone
Number of subjects: 270
Study: 11761770

Group type: EXPERIMENTAL
Intervention: 5,000 IU of retinyl palmitate and 30 mg of beta-carotene daily during pregnancy; 200,000 IU of retinyl palmitate at delivery
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 9436685

Group type: EXPERIMENTAL
Intervention: Air
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Echovist
Number of subjects: 32
Study: 8219523

Group type: EXPERIMENTAL
Intervention: 5 Hz TENS
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 100 Hz TENS
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 2000 Hz TENS
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 72
Study: 3301783

Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 38
Study: 29316450

Group type: EXPERIMENTAL
Intervention: Optimism training intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Attention-matched educational control
Number of subjects: 61
Study: 27341812

Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM™) plus Usual Care (UC)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Usual Care (UC) alone
Number of subjects: 750
Study: 24603902

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound (EBUS)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Combined EBUS/EUS
Number of subjects: 166

Group type: COMPARATOR
Intervention: Surgical mediastinal staging (SMS)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Endosonography
Number of subjects: 166
Study: 23183528

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 100 mg + PegIFN/RBV
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 200 mg + PegIFN/RBV
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg + PegIFN/RBV
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo + PegIFN/RBV
Number of subjects: 64
Study: 22151909

Group type: EXPERIMENTAL
Intervention: STAND programme (theory driven group structured education)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 178
Study: 18076588

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% FFS
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Terbinafine 5% FFS
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Terbinafine 10% FFS
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study: 16928600

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 14603503

Group type: EXPERIMENTAL
Intervention: Coground product (1:2:3 DHEA-α-Cd-glycine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated drug
Number of subjects: 0
Study: 10710409

Group type: EXPERIMENTAL
Intervention: 100 mg of ferrous sulfate (S) per day for 6 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 42
Study: 9173524

Group type: EXPERIMENTAL
Intervention: Hysterosalpingo-contrast sonography (HyCoSy) with Echovist 200
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patient discomfort assessment
Number of subjects: 50
Study: 8229720

Group type: EXPERIMENTAL
Intervention: Topical 0.03% flurbiprofen sodium
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 3101821

Group type: EXPERIMENTAL
Intervention: Respiratory health worker visits (monthly by a respiratory nurse)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no visits)
Number of subjects: 75
Study: 30428094

Group type: EXPERIMENTAL
Intervention: Inlay-cataract group (small aperture corneal inlay implanted in non-dominant eye)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inlay-cataract group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (conventional cataract surgery in both eyes)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 27592092

Group type: EXPERIMENTAL
Intervention: Severe renal dysfunction (GFR ≤30 mL/min)
Number of subjects: 2531

Group type: COMPARATOR
Intervention: Moderate renal dysfunction (GFR 31 to 60 mL/min)
Number of subjects: 2531

Group type: COMPARATOR
Intervention: None/mild renal dysfunction (GFR >60 mL/min)
Number of subjects: 2531
Study: 24015965

Group type: EXPERIMENTAL
Intervention: Weekly Sealed (WS) pedometer group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Unsealed (US) pedometer group
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Daily Sealed (DS) pedometer group
Number of subjects: 123
Study: 22349735

Group type: EXPERIMENTAL
Intervention: Mothers met the goal for TV/video viewing (<1 h/day)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Mothers met the goal for sugar-sweetened beverage intake (<1 serving/day)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Mothers met the goal for fast food intake (<1 time/week)
Number of subjects: 428
Study: 15994720

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (gradual substitution)
Number of subjects: 63
Study: 12427650

Group type: EXPERIMENTAL
Intervention: rFVIIa (90 microg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo and rFVIIa
Number of subjects: 16
Study: 9715340

Group type: EXPERIMENTAL
Intervention: Individual problem-solving treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group educational programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7657860

Group type: EXPERIMENTAL
Intervention: One-session AIDS education lecture
Number of subjects: 838

Group type: COMPARATOR
Intervention: Control group (no lecture)
Number of subjects: 838
Study: 2467983

Group type: EXPERIMENTAL
Intervention: Nalbuphine hydrochloride (0.375, 0.75, 1.5, 3 and 6 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0.1 and 0.2 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hydromorphone hydrochloride (4 and 8 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study: 322672

Group type: EXPERIMENTAL
Intervention: Carpipramine 3 X 50 mg per day for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo phase for 3 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 30
Study: 30367519

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (2,120 mg eicosapentaenoic acid/600 mg docosohexaenoic acid)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 24
Study: 28290162

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 2032

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 2032
Study: 24934401

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23151431

Group type: EXPERIMENTAL
Intervention: Short-term androgen suppression (STAS) with leuprorelin (22.5 mg every 3 months)
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Intermediate-term androgen suppression (ITAS) with leuprorelin (22.5 mg every 3 months)
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: ITAS plus zoledronic acid (4 mg every 3 months)
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Brachytherapy boost
Number of subjects: 1071
Study: 20089074

Group type: EXPERIMENTAL
Intervention: RTP-ASE Qontrast-generated images (A, beta, Axbeta) during adenosine stress
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combined A, beta and Axbeta image interpretation
Number of subjects: 67

Group type: COMPARATOR
Intervention: SPECT (99mTc-tetrofosmin)
Number of subjects: 67
Study: 18545204

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (25-g supplement)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Carbohydrate drinks (100 kcal and 250 kcal)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Energy-free placebo
Number of subjects: 60
Study: 16190917

Group type: EXPERIMENTAL
Intervention: 5 mg donepezil daily for 4 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10 mg donepezil daily for 8 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (normal, untreated controls)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Post-drug discontinuation
Number of subjects: 11
Study: 12135946

Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 11757256

Group type: EXPERIMENTAL
Intervention: Major Depression group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Dysthymia group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Induced sad mood state group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Normal-control group
Number of subjects: 81
Study: 7777104

Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy without iron supplementation (Group 3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy with iron supplementation (Group 4)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iron supplementation (Group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 40
Study: 2111979

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate delivered via face mask and spacer device (infants)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate delivered via face mask and nebuliser (infants and adults)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasal filtration of aerosol
Number of subjects: 16
Study: 111943

Group type: EXPERIMENTAL
Intervention: Oral fat load (100 g triglyceride) alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral fat load (100 g triglyceride) plus intravenous glucose infusion (0.7 g/kg/h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous glucose infusion (0.7 g/kg/h)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet for 3 weeks
Number of subjects: 6
Study: 30612771

Group type: EXPERIMENTAL
Intervention: TTO+MPFLR
Number of subjects: 42

Group type: COMPARATOR
Intervention: MPFLRa
Number of subjects: 42
Study: 26746221

Group type: EXPERIMENTAL
Intervention: Dry roasted, lightly salted hazelnuts
Number of subjects: 72

Group type: COMPARATOR
Intervention: Raw hazelnuts
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both forms of hazelnuts
Number of subjects: 72